HOME >> MEDICINE >> NEWS
Updated data compares DOXIL (R)/CAELYX (TM) (doxorubicin HCl liposome injection) to Topotecan

Bridgewater, NJ, November 4, 2003 Researchers have presented updated data comparing DOXIL/CAELYX (doxorubicin HCl liposome injection) to topotecan HCl in patients with recurrent ovarian cancer. These data, from a randomized, controlled, multi-center, open-label, Phase III clinical study, were presented during a poster session at the 12th meeting of the Federation of European Cancer Societies (ECCO 12) in Copenhagen, Denmark.1

The National Cancer Institute estimates that in 2003, 25,000 American women will be diagnosed with ovarian cancer, and 14,000 women will die from it.2 This analysis compared DOXIL and topotecan another common treatment for recurrent ovarian cancer in epithelial ovarian cancer patients whose disease recurred after or did not respond to first-line, platinum-based chemotherapy. The primary objective of this long-term follow up analysis was to measure the overall survival and progression-free survival of these patients.

Researchers reported the median overall survival was three weeks longer for patients treated with DOXIL compared to those treated with topotecan (63 and 60 weeks, respectively, HR 0.82 [95 percent CI = 0.68 to 1.00]; p = 0.05). In addition, the overall progression-free survival was 16.1 weeks for DOXIL compared to 17.0 weeks topotecan (HR 0.88 [95 percent CI = 0.73 to 1.06]; p = 0.171).

Among platinum-sensitive patients (those who had a PFS interval of greater than six months after first-line, platinum-based chemotherapy), the median survival of patients receiving DOXIL was 112 weeks versus 77 weeks for patients receiving topotecan (HR 0.63 [95 percent CI = 0.47 to 0.85]; p = 0.002). DOXIL patients also saw a significant advantage in median PFS versus those receiving topotecan (28.9 and 23.1 weeks, respectively, HR = 0.76 [95 percent CI = 0.58 to 1.00]; p = 0.046).

In the subset of patients with platinum-refractory disease (those whose disease progressed during in
'"/>


4-Nov-2003


Page: 1 2 3

Related medicine news :

1. Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence
2. Updated press release to October 2004 Cochrane Review
3. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web
4. Updated Results On Heart Assist Device Presented At International Transplant Meeting
5. Multi-center trial compares three medications in patients with heart failure
6. Study compares overnight dialysis to treatment in centers
7. Study compares clinical diagnoses and autopsy diagnoses in ICU deaths
8. New Commonwealth Fund analysis compares candidtes health care reform proposals
9. Study compares three weekly regimens of chemotherapy for lung cancer
10. Lung cancer screening trial compares CT and standard x-ray
11. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave

Post Your Comments:
(Date:7/23/2014)... 2014 FCCI Insurance Group has been ... American Heart Association for helping employees eat better and ... Fit-Friendly Worksite in 2013, 2011, and 2010, and as ... employee health and wellness an important priority. We’re committed ... at the top of their game, and we are ...
(Date:7/23/2014)... 2014 Being overweight is no longer ... suggests that eating a diet high in processed and ... the risk for a host of diseases and weight ... in the bloodstream. , The body makes cholesterol, ... can cause thick, hard plaque to build up, clogging ...
(Date:7/23/2014)... 2014 Researchers in Turkey say a ... yellow pigment in the spice turmeric, and an immunosuppressor ... lab. To read the full story on Surviving ... University in Ankara, Turkey pretreated mesothelioma cells ... them to two platinum-based chemotherapy drugs with promising results. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Daily Face & ... cheaper and safer alternative to Botox called Stem Cell ... is an anti-aging product used to help people smooth, tone, ... Serum can be used as a safe alternative to Botox, ... have any toxins or health risks as opposed to Botox. ...
(Date:7/23/2014)... Woodland Hills’ top cosmetic dentists ... bad breath that the condition is more than just a ... Jivraj and Dr. Mamaly Reshad of the Anacapa Dental Art ... some people may be overlooking an obvious sign of a ... an infection or chronic disease in the body,” Dr. Reshad ...
Breaking Medicine News(10 mins):Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 2Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 3Health News:Diet Doc’s Medical Weight Loss Programs Introduce Specialized Cholesterol Diet Plans that Deliver Fast Weight Loss and Reduce the Risk for Heart Attack and Stroke 2Health News:Diet Doc’s Medical Weight Loss Programs Introduce Specialized Cholesterol Diet Plans that Deliver Fast Weight Loss and Reduce the Risk for Heart Attack and Stroke 3Health News:New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma 2Health News:New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma 3Health News:Local Denver Skin Care Company Releases Safer Alternative to Botox 2Health News:Woodland Hills’ Top Cosmetic Dentists Offer 6 Tips on Causes of Bad Breath That Should Concern You 2Health News:Woodland Hills’ Top Cosmetic Dentists Offer 6 Tips on Causes of Bad Breath That Should Concern You 3Health News:Woodland Hills’ Top Cosmetic Dentists Offer 6 Tips on Causes of Bad Breath That Should Concern You 4Health News:Woodland Hills’ Top Cosmetic Dentists Offer 6 Tips on Causes of Bad Breath That Should Concern You 5
(Date:7/23/2014)... , July 23, 2014  Nearly 8,000 attendees will ... Cardinal Health,s annual Retail Business Conference (RBC), taking place ... Center. This year,s event encourages pharmacists to "Lead Change" ... communities and for their future. ... to network with their peers and learn new ways ...
(Date:7/23/2014)... Calif. , July 23, 2014  Cardica, Inc. (Nasdaq: ... financial results for its fiscal fourth quarter and year ended ... markets close. Cardica,s management will host a conference call at ... provide an update on the company,s business. Conference ... 7, 2014, at 4:30 p.m. Eastern Time via phone, please ...
(Date:7/23/2014)... a leader in R&D for new therapeutic solutions for the ... Growth Factor) has been designated as an orphan drug by ... The candidate drug, developed by the research of Dompe, has ... neurotrophic keratitis, a degenerative corneal disease that affects less than ... a cure. This is the second orphan drug designation by ...
Breaking Medicine Technology:Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4
Cached News: